Quarterly report pursuant to Section 13 or 15(d)

Investment in Saneron CCEL Therapeutics, Inc. ("Saneron") - Additional Information (Detail)

v3.2.0.727
Investment in Saneron CCEL Therapeutics, Inc. ("Saneron") - Additional Information (Detail)
 3 Months Ended 6 Months Ended 12 Months Ended
May. 31, 2015
USD ($)
May. 31, 2014
USD ($)
May. 31, 2015
USD ($)
Installment
May. 31, 2014
USD ($)
Nov. 30, 2014
USD ($)
Installment
Schedule of Equity Method Investments [Line Items]          
Equity method investment $ 684,000   $ 684,000   $ 684,000
Equity in losses $ (8,248) $ (76,076) $ (16,496) $ (189,651)  
Saneron [Member]          
Schedule of Equity Method Investments [Line Items]          
Ownership interest 33.00%   33.00%   33.00%
Goodwill $ 684,000   $ 684,000   $ 684,000
Equity method investment 684,000   684,000   684,000
Equity method investment, impairment loss     0   $ 0
Loan Saneron in quarterly payments an aggregate amount 300,000   300,000    
Initial loan amount 150,000   $ 150,000    
Additional quarterly payments | Installment     0   5
Date of maturity     5 years    
First initial quarterly payment     $ 37,500    
Equity in losses 8,248 76,076 $ 16,496 189,651  
Saneron [Member] | Valuation Allowance Investment [Member]          
Schedule of Equity Method Investments [Line Items]          
Equity in losses   37,500   112,500  
Saneron [Member] | Stock Awards [Member]          
Schedule of Equity Method Investments [Line Items]          
Equity in losses   $ 38,576   $ 77,151  
Saneron [Member] | Initial Loan [Member]          
Schedule of Equity Method Investments [Line Items]          
Additional quarterly payments | Installment     4    
Quarterly installments per quarter 37,500   $ 37,500    
Saneron [Member] | Additional Loan [Member]          
Schedule of Equity Method Investments [Line Items]          
Initial loan amount 150,000   $ 150,000    
Additional quarterly payments | Installment     4    
Quarterly installments per quarter $ 37,500   $ 37,500